Pedro L Dago

Medicine & Life Sciences

1. Bipolar Disorder 100%
2. Psychopharmacology 71%
3. Treatment-Resistant Depressive Disorder 69%
4. Aripiprazole 69%
5. Psychomotor Agitation 65%
6. Mood Disorders 60%
7. Antidepressive Agents 59%
8. Depressive Disorder 53%
9. Consensus 49%
10. Placebos 42%
11. Cognitive Dysfunction 42%
12. Schizophrenia 42%
13. Therapeutics 40%
14. Serotonin and Noradrenaline Reuptake Inhibitors 35%
15. Clinical Trials 33%
16. Major Depressive Disorder 26%
17. Pharmacokinetics 19%
18. olanzapine-fluoxetine combination 19%
19. Quetiapine Fumarate 13%
20. Cognitive Remediation 13%
21. Vulnerable Populations 10%
22. Depression 9%
23. Antipsychotic Agents 9%
24. Sample Size 9%
25. Reproducibility of Results 7%
26. Randomized Controlled Trials 6%
27. Placebo Effect 5%
28. Interviews 5%
29. Education 5%
30. Hope 5%
31. Costs and Cost Analysis 5%